ReAlta Life Sciences, Inc.
Mission: Address life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms.
To support this mission, ReAlta has developed a new class of drugs that deploy a set of unique multi-modal therapeutic capabilities.
PIC 1 Platform
The ReAlta technology platform, termed “PIC1”, is a family of over 75 engineered peptides. This platform is uniquely multi-modal, with Complement inhibition (C1), anti-inflammatory, anti-oxidant and antimicrobial capabilities. Lab and animal research show this platform has the potential to provide game-changing therapy for over 25 unmet or under-addressed medical needs.